Condition: Amyloidosis; Systemic · AL Amyloidosis · Sponsor: Jin Lu, MD
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%. Considering that Bcl-2 inhibitor is effective for AL amyloidosis with t(11; 14) and the median hematologic onset time of DBD is 7 days. We design a a prospective study on AL amyloidosis with t(11; 14). All patients receive DBD at the beginning. Patient will receive DBD for at least 6 cycles if achieve rapid hematologic response at day 7, while other patients will receive daratumumab, venetoclax and dexamethasone.
This description comes directly from the study's public registry record.
Jin Lu · +8613311491805 · jin1lu@sina.com
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Capital Medical University Affiliated Fuxing Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Anzhen Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Chinese PLA Eastern Theater General Hospital | Nanjing, Jiangsu, China | Recruiting |
| Qilu Hospital of Shandong University (QingDao) | Qingdao, Shandong, China | Recruiting |
| Qingdao Municipal Hospital | Qingdao, Shandong, China | Recruiting |
| The First Affiliated Hospital of Xi'an Jiao Tong University | Xi’an, Shanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06192979